The US Food and Drug Administration (FDA) has granted approval for Pfizer’s Braftovi (encorafenib) and Mektovi (binimetinib) combination to treat metastatic non-small cell lung cancer (NSCLC).

The combination treatment is indicated for usage in adult NSCLC patients with a BRAF V600E mutation.

The regulatory agency granted the approval based on findings from the Phase II PHAROS clinical trial currently under way.

The multicentre, open-label, single‑arm trial is assessing Braftovi plus Mektovi both in patients who are treatment-naïve and those who had previously received treatment.

PHAROS has already met key efficacy outcome measures of objective response rate (ORR) and duration of response in both subject groups.

Pfizer noted that the ORR was 75% in treatment-naïve subjects and that 59% responded for a minimum of 12 months.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Fatigue, diarrhoea, nausea and musculoskeletal pain were among the frequently reported all-causality adverse events in the trial.

The combination therapy is already approved by the FDA to treat unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.

Pfizer chief oncology research and development officer and executive vice-president Chris Boshoff stated: “Since its initial FDA approval in 2018, Braftovi plus Mektovi combination therapy has helped thousands of people living with BRAF V600E or V600K-mutant unresectable or metastatic melanoma. 

“We look forward to helping even more patients with our Braftovi plus Mektovi targeted combination therapy.”

The company holds the sole rights for Braftovi and Mektovi combination therapy in the US and Canada, and countries in Latin America, Africa and the Middle East.

In September 2023, Pfizer received marketing authorisation from the European Commission for Litfulo (ritlecitinib) to treat severe alopecia areata.